<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1817-5996</journal-id>
<journal-title><![CDATA[Revista Cubana de Reumatología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cuba Reumatol]]></abbrev-journal-title>
<issn>1817-5996</issn>
<publisher>
<publisher-name><![CDATA[Editorial CIMEQ]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1817-59962021000300009</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Desarrollo de artritis reumatoide refractaria al tratamiento convencional]]></article-title>
<article-title xml:lang="en"><![CDATA[Development of rheumatoid arthritis refractory to conventional treatment]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Crisol-Deza]]></surname>
<given-names><![CDATA[Diego André]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zurita-Borja]]></surname>
<given-names><![CDATA[Joselyn Linda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Crisol-Deza]]></surname>
<given-names><![CDATA[Yetsli Geraldine]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Privada San Juan Bautista Sociedad Científica de Estudiantes de Medicina de la Universidad Privada San Juan Bautista (SOCIEM-UPSJB) ]]></institution>
<addr-line><![CDATA[ Lima]]></addr-line>
<country>Peru</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Red de Eficacia Clínica y Sanitaria (REDECS)  ]]></institution>
<addr-line><![CDATA[ Lima]]></addr-line>
<country>Perú</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Privada San Juan Bautista Escuela Profesional de Medicina Humana ]]></institution>
<addr-line><![CDATA[ Lima]]></addr-line>
<country>Peru</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad Continental Sociedad Científica de Estudiantes de Medicina de la Universidad Continental (SOCEM UC) ]]></institution>
<addr-line><![CDATA[ Lima]]></addr-line>
<country>Perú</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>23</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1817-59962021000300009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1817-59962021000300009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1817-59962021000300009&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La artritis reumatoide es una enfermedad inflamatoria crónica sistémica que afecta del 0,4 % al 1 % de América Latina. Sus manifestaciones consisten en dolor crónico, destrucción articular y muerte prematura, afectando principalmente a mujeres. Mediante el puntaje del Health Assesment Questionnaire, se puede realizar un conteo de articulaciones tumefactas, presencia de nódulos reumatoides, factor reumatoide, velocidad de sedimentación globular, proteína C reactiva y erosiones en radiografía, los cuales estaban asociados con la elección del primer tratamiento con medicamentos antirreumáticos modificadores de la enfermedad (DMARD). El propósito de este estudio es determinar los principales estudios sobre el desarrollo de la artritis reumatoide refractaria al tratamiento convencional. Se realizó la búsqueda de literatura mediante una exploración de artículos en PubMed y SciELO; se consideraron artículos originales y de revisión, publicados en idioma inglés y español, haciendo uso de los descriptores. Se realizó una lectura preliminar de los artículos con el objetivo de seleccionar los que se ajustaban a nuestro propósito. Los documentos que tenían información con los aspectos formales se incluyeron en nuestra revisión, es decir, se seleccionó un total de 24 artículos. Es en este punto la observación clínica ha permitido describir que no todos los pacientes tienen el mismo curso de evolución de la enfermedad, incluso con tratamientos estandarizados a nivel mundial, y al evaluar los desenlaces de la enfermedad se sugiere que debe haber características de cada paciente que hacen que su enfermedad cause más daño en su evolución en comparación con otros pacientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Rheumatoid arthritis is a systemic chronic inflammatory disease that affects 0.4% to 1% of Latin America, manifested by chronic pain, joint destruction and premature death, affecting mainly women. Using the Health Assessment Questionnaire score, a count of swollen joints, presence of rheumatoid nodules, rheumatoid factor, erythrocyte sedimentation rate, C-reactive protein and erosions in radiography, were associated with the choice of the first treatment with disease-modifying antirheumatic drugs (DMARDs). To determine the main studies that ensure efficacy towards the development of rheumatoid arthritis refractory to conventional treatment. The literature search was carried out by means of an exploration of articles in PubMed and SciELO; Original and review articles were considered, published in English and Spanish, making use of the descriptors, a preliminary reading of the articles was carried out with the aim ofSelect those that fit our purpose, the documents that had information with the formal aspects, were included in our review, that is, a rigorous reading, which selected a total of 24 articles. It is at this point that clinical observation has made it possible to describe that not all patients have the same course of evolution of the disease, even with standardized treatments worldwide, and when evaluating the outcomes of the disease it is suggested that there must be characteristics of each patients who cause their disease to cause more damage in their evolution compared to other patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[artritis reumatoide]]></kwd>
<kwd lng="es"><![CDATA[antirreumáticos]]></kwd>
<kwd lng="es"><![CDATA[productos biológicos]]></kwd>
<kwd lng="en"><![CDATA[rheumatoid arthritis]]></kwd>
<kwd lng="en"><![CDATA[antirheumatic]]></kwd>
<kwd lng="en"><![CDATA[biological products]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Massardo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Artritis reumatoide temprana]]></article-title>
<source><![CDATA[Rev Méd Chile]]></source>
<year>2008</year>
<volume>136</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1468-75</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Atsumi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yamamoto]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Takeuchi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yamanka]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ishiguro]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression]]></article-title>
<source><![CDATA[Annals of the Rheumatic Diseases]]></source>
<year>2016</year>
<volume>75</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>75-83</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genomics, transcriptomics and proteomics to elucidate the pathogenesis of rheumatoid arthritis]]></article-title>
<source><![CDATA[Rheumatol Int]]></source>
<year>2017</year>
<volume>37</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1257-65</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scherer]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Häupl]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Burmester]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The etiology of rheumatoid arthritis]]></article-title>
<source><![CDATA[J Autoimmun]]></source>
<year>2020</year>
<volume>110</volume>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rais]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Saeed]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Haider]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatoid arthritis clinical features and management strategies at an urban tertiary facility in Pakistan]]></article-title>
<source><![CDATA[J Pak Med Assoc]]></source>
<year>2014</year>
<volume>64</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1435-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aletaha]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Precision medicine and management of rheumatoid arthritis]]></article-title>
<source><![CDATA[J Autoimmun]]></source>
<year>2020</year>
<volume>32</volume>
<numero>27</numero>
<issue>27</issue>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verstappen]]></surname>
<given-names><![CDATA[SMM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The impact of socio-economic status in rheumatoid arthritis]]></article-title>
<source><![CDATA[Rheumatology (Oxford)]]></source>
<year>2017</year>
<volume>56</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1051-2</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[SMB]]></given-names>
</name>
<name>
<surname><![CDATA[Moya]]></surname>
<given-names><![CDATA[AMGS]]></given-names>
</name>
<name>
<surname><![CDATA[Mora]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aproximación de discapacidad en artritis reumatoide. Resultados de un programa de atención integral]]></article-title>
<source><![CDATA[Rev Colomb Reumatol]]></source>
<year>2017</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>138-44</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malm]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Bergman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Andersson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bremander]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictors of severe self-reported disability in RA in a long-term follow-up study]]></article-title>
<source><![CDATA[Disability and Rehabilitation]]></source>
<year>2015</year>
<volume>37</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>686-91</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Cock]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hyrich]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management]]></article-title>
<source><![CDATA[Best Practice &amp; Research Clinical Rheumatology]]></source>
<year>2018</year>
<volume>32</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>869-86</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Saag]]></surname>
<given-names><![CDATA[KG]]></given-names>
</name>
<name>
<surname><![CDATA[Bridges Jr]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Akl]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Raveendhara]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis]]></article-title>
<source><![CDATA[Arthritis &amp; Rheumatology]]></source>
<year>2016</year>
<volume>68</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-26</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dumusc]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[So]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Complications and systemic manifestations of rheumatoid arthritis]]></article-title>
<source><![CDATA[Rev Med Suisse]]></source>
<year>2014</year>
<volume>10</volume>
<numero>421</numero>
<issue>421</issue>
<page-range>592-4</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Østergaard]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Møller-Bisgaard]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatoid arthritis: Is imaging needed to define remission in rheumatoid arthritis?]]></article-title>
<source><![CDATA[Nat Rev Rheumatol]]></source>
<year>2014</year>
<volume>10</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>326-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rais]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Saeed]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Haider]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatoid arthritis clinical features and management strategies at an urban tertiary facility in Pakistan]]></article-title>
<source><![CDATA[J Pak Med Assoc]]></source>
<year>2014</year>
<volume>64</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1435-7</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pisetsky]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances in the Treatment of Rheumatoid Arthritis: Costs and Challenges]]></article-title>
<source><![CDATA[N C Med J]]></source>
<year>2017</year>
<volume>78</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>337-40</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hyndman]]></surname>
<given-names><![CDATA[IJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatoid arthritis: past, present and future approaches to treating the disease]]></article-title>
<source><![CDATA[Int J Rheum Dis]]></source>
<year>2017</year>
<volume>20</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>417-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Howard]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[McCormick]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pui]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Buddington]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Harvey]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preventing and Managing Toxicities of High-Dose Methotrexate]]></article-title>
<source><![CDATA[Oncologist]]></source>
<year>2016</year>
<volume>21</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1471-82</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smolen]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Landewé]]></surname>
<given-names><![CDATA[RBM]]></given-names>
</name>
<name>
<surname><![CDATA[Bijlsma]]></surname>
<given-names><![CDATA[JWJ]]></given-names>
</name>
<name>
<surname><![CDATA[Burmester]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Dougados]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kerschbaumer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EULAR Recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2020</year>
<volume>79</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>685-99</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Remuzgo-Martínez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Genre]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[López-Mejías]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ubilla]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mijares]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Pina]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis]]></article-title>
<source><![CDATA[Sci]]></source>
<year>2016</year>
<volume>6</volume>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yamanaka]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and treatment of rheumatoid arthritis: toward the best practice. How to use the guideline in the management of rheumatoid arthritis?]]></article-title>
<source><![CDATA[Clin Calcium]]></source>
<year>2018</year>
<volume>28</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>607-10</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[OZ]]></given-names>
</name>
<name>
<surname><![CDATA[Egüez]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fusté]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Borges]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[OL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización clínico-epidemiológica de pacientes con artritis reumatoide: características tomográficas y evolución]]></article-title>
<source><![CDATA[Rev Finlay]]></source>
<year>2015</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>264-74</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rachapalli]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kiely]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Choy]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[First-line DMARD choice in early rheumatoid arthritis (do prognostic factors play a role?]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2018</year>
<volume>49</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1267-71</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yu-Hsiang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ming-Shi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IL - 20 in rheumatoid arthritis]]></article-title>
<source><![CDATA[Drug Discovery Today]]></source>
<year>2017</year>
<volume>22</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>960-4</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Audo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Daien]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Papon]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lukas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vittecoq]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Hahne]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort]]></article-title>
<source><![CDATA[Arthritis Res Ther]]></source>
<year>2015</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
